■世界卫生组织于2023年5月5日宣布2019年冠状病毒病(COVID-19)大流行结束。开发了几种疫苗,并公布了有关其有效性的新数据。然而,疫苗的临床试验是在Omicron变体出现之前进行的,有些人群仍需要对疫苗的有效性进行测试.本研究的总体目标是分析COVID-19疫苗在Omicron变种之前和之后在NuevoLeon人群中考虑合并症的患者中接种的效果,墨西哥。
■墨西哥社会保障研究所的流行病学COVID-19数据来自墨西哥东北部的67家医院,从2020年7月到2023年5月,共收集了669,393个案例,255,819报道了SARS-CoV-2阳性逆转录定量聚合酶链反应(RT-qPCR)测试或COVID-19抗原快速测试阳性。
■在Omicron之前(BO,2020-2021年),两剂COVID-19疫苗接种14天后,BNT162b2和ChAdOx1疫苗在非共病和所有共病亚组中对感染有效,而在Omicron(AO,2022年至2023年),没有任何疫苗对感染没有显著的效果。关于住院BO,BNT162b2,ChAdOx1,CoronaVac和mRNA-1273显着保护非合并症患者,而BNT162b2,ChAdOx1和mRNA-1273则保护所有合并症亚组免于住院。AO,BNT162b2,ChAdOx1,CoronaVac和mRNA-1273对非合并症患者的住院有效,而对于大多数合并症患者,BNT162b2,ChAdOx1和CoronaVac对住院有效。在BO期间,使用大多数疫苗可以保护非共病患者免受COVID-19的死亡,而在高血压患者中,使用mRNA-1273疫苗的AO效果降低,和糖尿病。
■BO,COVID-19疫苗对感染有效,住院治疗,和死亡,而AO,COVID-19疫苗未能保护人群免受COVID-19感染。观察到AO对住院和死亡的不同有效性。
UNASSIGNED: The end of the coronavirus disease 2019 (COVID-19) pandemic has been declared by the World Health Organization on May 5, 2023. Several vaccines were developed, and new data is being published about their effectiveness. However, the clinical trials for the vaccines were performed before the Omicron variant appeared and there are population groups where vaccine effectiveness still needs to be tested. The overarching goal of the present study was to analyze the effects of COVID-19 vaccination before and after the Omicron variant in patients considering comorbidities in a population from Nuevo Leon, Mexico.
UNASSIGNED: Epidemiological COVID-19 data from the Mexican Social Security Institute were collected from 67 hospitals located in northeastern Mexico, from July 2020 to May 2023, and a total of 669,393 cases were compiled, 255,819 reported a SARS-CoV-2 positive reverse transcription quantitative polymerase chain reaction (RT-qPCR) test or a positive COVID-19 antigen rapid test.
UNASSIGNED: Before Omicron (BO, 2020-2021), after 14 days of two doses of COVID-19 vaccine, BNT162b2 and ChAdOx1 vaccines were effective against infection in non-comorbid and all comorbid subgroups, whereas after Omicron (AO, 2022- 2023) there was no significant effectiveness against infection with none of the vaccines. Regarding hospitalization BO, BNT162b2, ChAdOx1, CoronaVac and mRNA-1273 significantly protected non-comorbid patients whereas BNT162b2, ChAdOx1, and mRNA-1273, protected all comorbid subgroups against hospitalization. AO, BNT162b2, ChAdOx1, CoronaVac and mRNA-1273 were effective against hospitalization in non-comorbid patients whereas for most comorbid subgroups BNT162b2, ChAdOx1 and CoronaVac were effective against hospitalization. Non-comorbid patients were protected against death as an outcome of COVID-19 during the BO period with most vaccines whereas a reduction in effectiveness was observed AO with mRNA-1273 vaccines in patients with hypertension, and diabetes mellitus.
UNASSIGNED: BO, COVID-19 vaccines were effective against infection, hospitalization, and death whereas AO, COVID-19 vaccines failed to protect the population from COVID-19 infection. A varying effectiveness against hospitalization and death is observed AO.